Byk Gulden Lomberg Chemische Fabrik Gmbh

Altana Pharma Ag

Nycomed Gmbh

Takeda Gmbh

Christian Schudt

Ulrich Kilian

Friedrich Grimminger

Torsten Dunkern

Hossein Ardeschir Ghofrani

Manfred Kaps

Bernhard Rosengarten

Armin Hatzelmann

Degenhard Marx

Hermann Tenor

Hermann Amschler

Rolf Beume

Saadia Eddahibi

Serge Adnot

Thorsten Dunkern

The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.

Roflumilast for the treatment of pulmonary hypertension

The present invention is concerned with the use of PDE5 inhibitors in medicine.

Use for PDE5 inhibitors

The invention relates to the combined administration of PDE inhibitors and &#x3b2;adrenoceptor agonists for the treatment of respiratory tract disorders.

Synergistic combination

The invention relates to the combined administration of PDE inhibitors and &bgr; adrenoceptor agonists for the treatment of respiratory tract disorders.

A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists

Pyridazines

Growing community of inventors

Constance, Germany

Christian Schudt